USANA Health Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
USANA Health Sciences, Inc. (USNA) filed a Current Report on Form 8-K dated June 27, 2025. The filing reports the entry into a material definitive agreement and the creation of a direct financial obligation through a new credit facility.
Key Financial Metrics and Debt Structure
The Company entered into a Third Amended and Restated Credit Agreement with Bank of America, N.A., and other lenders. Key terms include:
- Credit Facility: A revolving credit limit of up to $75 million.
- Expansion Option: The Company may request to increase the aggregate commitment by up to $200 million, subject to conditions.
- Collateral: Obligations are secured by the pledge of capital stock of the Company's subsidiaries.
- Interest Rates: Based on Term SOFR, Base Rate, Daily Simple SOFR, or Swingline rates plus applicable margins.
- Dividends and Repurchases: The agreement does not restrict cash dividends or share repurchases.
Material Changes and Covenants
The new agreement imposes two primary financial covenants effective for the fiscal quarter ending June 28, 2025:
- Consolidated EBITDA Covenant:
- $80 million minimum for the four prior fiscal quarters ending June 28, 2025, through July 4, 2026.
- $100 million minimum for the four prior fiscal quarters ending October 3, 2026, and thereafter.
- Debt-to-EBITDA Ratio: Consolidated funded debt to consolidated EBITDA ratio must not exceed 2.0 to 1.0.
The filing text does not provide specific revenue, profit, cash flow, or current liquidity figures for the reporting period, as this 8-K focuses solely on the credit agreement terms.
Outlook, Risks, and Contingencies
The Credit Agreement includes customary events of default, such as failure to pay principal or interest, covenant breaches, insolvency, or receivership. In the event of default, Bank of America may declare all amounts immediately due and payable, terminate commitments, and exercise remedies under the Pledge Agreement. Insolvency-related defaults trigger automatic termination of commitments and immediate due dates for outstanding loans.
Investor Verification Checklist
- Verify the Company's current consolidated EBITDA to ensure compliance with the $80 million covenant threshold for the quarter ending June 28, 2025.
- Confirm the current consolidated funded debt to EBITDA ratio remains at or below 2.0 to 1.0.
- Review the full text of the Third Amended and Restated Credit Agreement (Exhibit 10.1) for specific margin rates and conditions for the $200 million expansion option.
- Monitor for any future filings regarding the utilization of the $75 million revolving facility.